关键词：ACS；血液；减少流向心脏；CV疾病；ST-跟踪心电图；STEMI；NSTEMI；UA
摘 要：ACS is a group of CV diseases characterized by sudden and reduced flow of blood to the heart. The syndrome is a major cause of concern associated with increased healthcare expenses, frequent recurrences and hospitalizations, and low mortality rate. On the basis of the damage to the heart muscle and changes in the ST-tracing of the ECG, ACS is categorized into STEMI NSTEMI, and UA. ACS is treatable if diagnosed immediately, with the treatment options varying depending on the signs, symptoms, and overall health condition of the patient.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Disease Overview

06.1 Understanding the Disease

06.2 Burden of Disease

06.3 Etiology

06.4 Pathophysiology

Myocardial Dysfunction

MI

Electrical Dysfunction

06.5 Prognosis

06.6 Epidemiology

Prevalence of Coronary Artery Disease

06.7 Diagnosis

ECG

Blood Tests

Nuclear Scan

CT

06.8 Management

07. ACS Pipeline Landscape

07.1 Key Pipeline Molecules

08. Market Landscape

08.1 Market Overview

08.2 Market Size and Forecast

08.3 Five Forces Analysis

09. Market Segmentation by ECG Output

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

18.1 Competitive Scenario

Key News

Mergers and Acquisitions

18.2 Market Share Analysis 2014

AstraZeneca

Bristol-Myers Squibb

Eli Lilly

GlaxoSmithKline

Sanofi

18.3 Other Prominent Vendors

19. Key Vendor Analysis

19.1 AstraZeneca

Key Facts

Business Overview

Business Segmentation by Revenue 2013

Business Segmentation by Revenue 2011-2013

Revenue by Geography

Business Strategy

Key Developments

SWOT Analysis

19.2 Bristol-Myers Squibb

Key Facts

Business Overview

Key Product Offerings

Revenue by Geography

Business Strategy

Key Information

SWOT Analysis

19.3 Eli Lilly

Key Facts

Business Overview

Business Segmentation by Revenue

Revenue by Geography

Business Strategy

Key Information

SWOT Analysis

19.4 GlaxoSmithKline

Key Facts

Business Overview

Business Segmentation

Business Segmentation by Revenue 2012 and 2013

Revenue by Geography

Pipeline Products

Business Strategy

Key Information

SWOT Analysis

19.5 Sanofi

Key Facts

Business Description

Business Segmentation

Revenue by Business Segmentation

Revenue Comparison 2012 and 2013

Revenue by Geography

Business Strategy

Key Developments

SWOT Analysis

20. Other Reports in this Series